| 創建日期 | 上市日期 | 董事長 | 總經理 |
|---|---|---|---|
| 54/12/22 | 101/05/03 | 詹啟賢 | 留忠正 |
| EPS | 本益比 | 股價淨值比 | 現金殖利率 |
| -0.57(Q2) | 0 | 2.43 | 0% |
| 實收資本額 | 已發行普通股 | ||
| 4,295,077,500 | 429,507,750 | ||
| 主要經營業務 | |||
| 血清、疫苗、檢驗試劑、生物製劑及其菌液、原料等之加工製造買賣有關西藥、動物用藥品、化學品及飼料添加物等之加工製造買賣前各項產品之進出口貿易與代理 | |||
| 公司網址 | |||
| adimmune.com.tw/ | |||
國光生(4142) 月營收報表
| 年度/月份 | 營業收入（單位：千元） | 累計營業收入（單位：千元） | |||||
|---|---|---|---|---|---|---|---|
| 單月營收 | 去年同月營收 | 單月月增率 | 單月年增率 | 累計營收 | 去年累計營收 | 累積年增率 | |
| 2023/08 | 624,945 | 109,142 | 462.4% | 472.6% | 988,323 | 966,217 | 2.3% |
| 2023/07 | 111,119 | 277,341 | 194.2% | -59.9% | 363,378 | 857,075 | -57.6% |
| 2023/06 | 37,774 | 491,433 | 1791.5% | -92.3% | 252,259 | 579,734 | -56.5% |
| 2023/05 | 1,997 | 20,211 | -95.3% | -90.1% | 214,485 | 88,300 | 142.9% |
| 2023/04 | 42,778 | 15,291 | -52.3% | 179.8% | 212,488 | 68,089 | 212.1% |
| 2023/03 | 89,676 | 19,795 | 119.7% | 353% | 169,710 | 52,798 | 221.4% |
| 2023/02 | 40,825 | 29,901 | 4.1% | 36.5% | 80,034 | 33,003 | 142.5% |
| 2023/01 | 39,209 | 3,102 | -81.1% | 1164% | 39,209 | 3,102 | 1164% |
| 2022/12 | 207,592 | 53,447 | 95.5% | 288.4% | 2,251,625 | 1,641,061 | 37.2% |
| 2022/11 | 106,205 | 210,279 | -60.8% | -49.5% | 2,044,033 | 1,587,614 | 28.7% |
| 2022/10 | 270,805 | 529,052 | -61.3% | -48.8% | 1,937,828 | 1,377,335 | 40.7% |
| 2022/09 | 700,805 | 464,745 | 542.1% | 50.8% | 1,667,022 | 848,283 | 96.5% |
| 2022/08 | 109,142 | 235,780 | -60.6% | -53.7% | 966,217 | 383,538 | 151.9% |
| 2022/07 | 277,341 | 52,811 | -43.6% | 425.1% | 857,075 | 147,757 | 480% |
| 2022/06 | 491,433 | 68,932 | 2331.5% | 612.9% | 579,734 | 94,946 | 510.6% |
| 2022/05 | 20,211 | 17,106 | 32.2% | 18.1% | 88,300 | 26,014 | 239.4% |
| 2022/04 | 15,291 | 1,977 | -22.8% | 673.4% | 68,089 | 8,908 | 664.3% |
| 2022/03 | 19,795 | 4,955 | -33.8% | 299.5% | 52,798 | 6,931 | 661.8% |
| 2022/02 | 29,901 | 1,155 | 863.9% | 2488.8% | 33,003 | 1,975 | 1571% |
| 2022/01 | 3,102 | 821 | -94.2% | 277.8% | 3,102 | 821 | 277.8% |
| 2021/12 | 53,447 | 127,434 | -74.6% | -58% | 1,641,061 | 1,869,160 | -12.2% |
| 2021/11 | 210,279 | 79,472 | -60.3% | 164.6% | 1,587,614 | 1,741,726 | -8.8% |
| 2021/10 | 529,052 | 614,442 | 13.8% | -13.9% | 1,377,335 | 1,662,254 | -17.1% |
| 2021/09 | 464,745 | 447,539 | 97.1% | 3.8% | 848,283 | 1,047,812 | -19% |
| 2021/08 | 235,780 | 168,283 | 346.5% | 40.1% | 383,538 | 600,273 | -36.1% |
| 2021/07 | 52,811 | 1,898 | -23.4% | 2682.4% | 147,757 | 431,989 | -65.8% |
| 2021/06 | 68,932 | 51,715 | 303% | 33.3% | 94,946 | 430,092 | -77.9% |
| 2021/05 | 17,106 | 6,350 | 765.3% | 169.4% | 26,014 | 378,377 | -93.1% |
| 2021/04 | 1,977 | 5,014 | -60.1% | -60.6% | 8,908 | 372,027 | -97.6% |
| 2021/03 | 4,955 | 5,177 | 329% | -4.3% | 6,931 | 367,013 | -98.1% |
| 2021/02 | 1,155 | 4,596 | 40.7% | -74.9% | 1,975 | 361,836 | -99.4% |
| 2021/01 | 821 | 357,241 | -99.3% | -99.8% | 821 | 357,241 | -99.8% |
| 2020/12 | 127,434 | 274,030 | 60.3% | -53.5% | 1,869,160 | 1,299,689 | 43.8% |
| 2020/11 | 79,472 | 189,774 | -87.1% | -58.1% | 1,741,726 | 1,025,658 | 69.8% |
| 2020/10 | 614,442 | 163,585 | 37.3% | 275.6% | 1,662,254 | 835,884 | 98.9% |
| 2020/09 | 447,539 | 269,008 | 165.9% | 66.4% | 1,047,812 | 672,298 | 55.8% |
國光生(4142) 歷年營收季增率
| 年度/季別 | 營收季增率 | 近4季營收季增率 | 年度/季別 | 營收季增率 | 近4季營收季增率 |
|---|---|---|---|---|---|
| 2023Q2 | -51.36% | -18.76% | 2020Q3 | 879.28% | 7.09% |
| 2023Q1 | -70.97% | 5.19% | 2020Q2 | -82.81% | -2.63% |
| 2022Q4 | -46.23% | -8.46% | 2020Q1 | -41.50% | 23.61% |
| 2022Q3 | 106.34% | 15.71% | 2019Q4 | 23.79% | 20.46% |
| 2022Q2 | 898.02% | 26.02% | 2019Q3 | 381.25% | 21.61% |
| 2022Q1 | -93.34% | 2.79% | 2019Q2 | 74.97% | 9.21% |
| 2021Q4 | 5.24% | -1.71% | 2019Q1 | -85.20% | -1.22% |
| 2021Q3 | 755.92% | 8.84% | 2018Q4 | 29.06% | 30.81% |
| 2021Q2 | 1169.87% | 1.65% | 2018Q3 | 934.45% | 16.50% |
| 2021Q1 | -99.16% | -19.26% | 2018Q2 | -56.64% | -3.50% |
| 2020Q4 | 32.96% | 11.58% | 2018Q1 | -67.01% | -0.91% |
評論0